Instrument Inactif

Communiqués Clementia Pharmaceuticals Inc

Actions

CA1855751071

Recherche biotechnologique et médicale

Communiqués

11/04/19	Clementia Pharmaceuticals Inc. Announces Receipt of Final Court Approval for Plan of Arrangement With Ipsen S.A.	GL
09/04/19	Clementia Pharmaceuticals Inc. Shareholders Approve Plan of Arrangement With Ipsen S.A.	GL
01/03/19	WeissLaw LLP Investigates Clementia Pharmaceuticals, Inc.	PR
20/02/19	Clementia Announces Date of Fourth Quarter and Full Year 2018 Results and Presentation at 8th Annual SVB Leerink Global Healthcare Conference	GL
30/11/18	Clementia Announces the Departure of Chief Commercial Officer	GL
21/11/18	Clementia to Present at the Evercore ISI HealthCONx Conference	GL
07/11/18	Clementia Reports Third Quarter 2018 Operating Results and Pipeline Updates	GL
30/10/18	Clementia Announces Pricing of Public Offering of Common Shares	GL
29/10/18	Clementia Announces Proposed Public Offering of Common Shares	GL
23/10/18	Clementia Announces Plan to Submit a New Drug Application for Palovarotene for the Treatment of FOP Based on Positive Phase 2 Results	GL
02/10/18	Clementia Initiates Phase 1 Clinical Trial of Palovarotene Eye Drop Formulation in Healthy Volunteers	GL
26/09/18	Clementia Announces Updated Phase 2 Part B Data on Palovarotene for FOP	GL
05/09/18	Clementia to Present at ASBMR 2018 and Upcoming Investor Conferences	GL
16/08/18	Clementia Announces Completion of Enrollment in Phase 3 MOVE Trial for FOP	GL
09/08/18	Clementia Reports Second Quarter 2018 Operating Results and Pipeline Updates	GL
31/05/18	Clementia to Present at the Jefferies 2018 Global Healthcare Conference	GL
23/05/18	Clementia Reports Positive Phase 2 Part B Data Showing Treatment with Palovarotene Significantly Reduces New Bone Growth in Patients with FOP	GL
09/05/18	Clementia Reports First Quarter 2018 Operating Results and Pipeline Updates	GL
20/04/18	Clementia Initiates Phase 2 MO-Ped Trial for Palovarotene in Patients with Multiple Osteochondromas	GL
06/03/18	Clementia to Present at the Cowen and Company 38th Annual Health Care Conference	GL
28/02/18	Clementia Reports 2017 Operating Results and Business Highlights	GL
07/02/18	Clementia to Participate in Leerink Partners 7th Annual Global Healthcare Conference	GL
31/01/18	Clementia Appoints Industry Veteran Pierre Legault to its Board of Directors	GL
03/01/18	Clementia Announces Presentation at the J.P. Morgan 36th Annual Healthcare Conference	GL
12/12/17	Clementia Initiates Pivotal Phase 3 MOVE Trial for Palovarotene in Patients with Fibrodysplasia Ossificans Progressiva	GL